{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:48:35Z","timestamp":1793969315662,"version":"4.8.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313646"],"award-info":[{"award-number":["2017A030313646"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2018.01600","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:15:51Z","timestamp":1532477751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":136,"title":["Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Xiaojun","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishou","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.32","article-title":"Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome.","volume":"7","author":"Acosta","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B2","first-page":"185","article-title":"The fecal microbial population in the irritable bowel syndrome.","volume":"5","author":"Balsari","year":"1982","journal-title":"Microbiologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.00691-09","article-title":"Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1152\/ajpgi.00154.2011","article-title":"Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.","volume":"301","author":"Carroll","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891","article-title":"Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"key":"B6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1365-2036.2012.05007","article-title":"Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome.","volume":"35","author":"Chassard","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review.","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11739-010-0496-0","article-title":"Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome.","volume":"6","author":"Di Stefano","year":"2011","journal-title":"Intern. Emerg. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.13928","article-title":"Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.","volume":"45","author":"Gatta","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome.","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/gutjnl-2013-305994","article-title":"Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome.","volume":"63","author":"Jalanka-Tuovinen","year":"2014","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/gutjnl-2011-301501","article-title":"An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.","volume":"61","author":"Jeffery","year":"2012","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nbt.2676","article-title":"Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences.","volume":"31","author":"Langille","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.dld.2017.01.142","article-title":"Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis.","volume":"49","author":"Liu","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","article-title":"Rifaximin modulates the colonic microbiota of patients with Crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system.","volume":"65","author":"Maccaferri","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","first-page":"139","article-title":"Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.","volume":"52","author":"Majewski","year":"2007","journal-title":"Adv. Med. Sci."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-134","article-title":"Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota.","volume":"10","author":"Noor","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13437","article-title":"Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.","volume":"43","author":"Pimentel","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrgastro.2017.29","article-title":"Gut microbiome as a clinical tool in gastrointestinal disease management: Are we there yet?","volume":"14","author":"Quigley","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.","volume":"141","author":"Rajilic-Stojanovic","year":"2011","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1099\/jmm.0.000366","article-title":"Modulation of intestinal barrier function to ameliorate Salmonella infection in mice by oral administration of fermented milks produced with Lactobacillus plantarum MTCC 5690 - a probiotic strain of Indian gut origin.","volume":"65","author":"Rokana","year":"2016","journal-title":"J. Med. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation.","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CEG.S89999","article-title":"Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach.","volume":"8","author":"Soldi","year":"2015","journal-title":"Clin. Exp. Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2982.2009.01427","article-title":"Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.","volume":"22","author":"Tana","year":"2010","journal-title":"Neurogastroenterol. Motil."},{"key":"B26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jgh.12862","article-title":"Small intestinal bacterial overgrowth as an uncommon cause of false positive lactose hydrogen breath test among patients with diarrhea-predominant irritable bowel syndrome in Asia.","volume":"30","author":"Wang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2036.2004.01939","article-title":"A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling.","volume":"19","author":"Xiong","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/19490976.2016.1215805","article-title":"Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.","volume":"7","author":"Zeber-Lubecka","year":"2016","journal-title":"Gut Microbes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jgh.13471","article-title":"Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis.","volume":"32","author":"Zhuang","year":"2016","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.01600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:15:52Z","timestamp":1532477752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmicb.2018.01600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2018.01600"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2018.01600","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"article-number":"1600"}}